Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Senti Biosciences (SNTI)
In a report issued on May 15, Geulah Livshits from Chardan Capital reiterated a Buy rating on Senti Biosciences, with a price target of $12.00. The company’s shares closed last Friday at $1.01.
According to TipRanks.com, Livshits is a 4-star analyst with an average return of 8.9% and a 36.3% success rate. Livshits covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Lexeo Therapeutics, Inc., and Iovance Biotherapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Senti Biosciences with a $12.00 average price target, a 1032.1% upside from current levels. In a report issued on May 15, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.
